文献速递免疫规划

脂质体疫苗中的重组烟曲霉抗原Asp f 3和Asp f 9可保护小鼠抵御侵袭性肺曲霉病

Recombinant Aspergillus fumigatus antigens Asp f 3 and Asp f 9 in liposomal vaccine protect mice against invasive pulmonary aspergillosis.
PubMed 文献 · Vaccine · 2022-06-06

本研究利用小鼠模型评估化学偶联重组烟曲霉表面抗原Asp f 3和Asp f 9的VesiVax®佐剂脂质体(VesiVax® Af3/9)对侵袭性肺曲霉病的保护效果。结果显示,VesiVax® Af3/9对唑类耐药烟曲霉菌株感染具有保护作用,表现为生存改善和肺部真菌负荷降低,且与脾细胞IL-4上调和血清Asp f 3、Asp f 9特异性IgG2a抗体相关;VesiVax® Af3/9联合后续脂质体两性霉素B(AmBisome®)生存优于任一单独治疗。

要点

  • VesiVax® Af3/9在类固醇抑制和中性粒细胞减少小鼠中均对唑类耐药烟曲霉感染有保护作用。
  • 保护作用与脾细胞IL-4上调和血清Asp f 3、Asp f 9特异性IgG2a抗体相关。
  • VesiVax® Af3/9联合后续脂质体两性霉素B(AmBisome®)生存优于任一单独治疗。

核心结论

  • 预防性接种VesiVax® Af3/9是抵御侵袭性肺曲霉病的有前景方法,即使在当前疗法因疾病面貌变化而失效的情况下亦然。

研究设计与样本

  • 小鼠模型研究,评估化学偶联重组烟曲霉表面抗原Asp f 3和Asp f 9的VesiVax®佐剂脂质体(VesiVax® Af3/9)对唑类耐药烟曲霉菌株感染的保护效果。

主要发现

  • 在类固醇抑制和中性粒细胞减少小鼠中,VesiVax® Af3/9对唑类耐药烟曲霉菌株感染具有保护作用,表现为生存改善和肺部真菌负荷降低。
  • 保护作用与脾细胞产生的IL-4上调以及血清中Asp f 3和Asp f 9特异性IgG2a抗体的存在相关。
  • 接受VesiVax® Af3/9并后续给予脂质体两性霉素B(AmBisome®)的小鼠生存优于仅接受任一单独治疗者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Invasive pulmonary aspergillosis caused by the ubiquitous mold Aspergillus fumigatus is a major threat to immunocompromised patients, causing unacceptably high mortality despite standard of care treatment, and costing an estimated $1.2 billion annually. Treatment for this disease has been complicated by the emergence of azole resistant strains of A. fumigatus, rendering first-line antifungal therapy ineffective. The difficulties in treating infected patients using currently available drugs make immunotherapeutic vaccination an attractive option. Here, we demonstrate the efficacy of VesiVax® adjuvant liposomes, consisting of a combination of two individual liposome preparations, to which two recombinant A. fumigatus surface antigens, Asp f 3 and Asp f 9 (VesiVax® Af3/9), have been chemically conjugated. Using a murine model, we demonstrate that VesiVax® Af3/9 is protective against infection by azole resistant strains of A. fumigatus in both steroid-suppressed and neutropenic mice as quantified by improved survival and reduced fungal burden in the lungs. This protection correlates with upregulation of IL-4 produced by splenocytes, and the presence of Asp f 3 and Asp f 9 specific IgG2a antibodies in the serum of mice given VesiVax® Af3/9. Furthermore, mice given VesiVax® Af3/9 with a subsequent course of liposomal amphotericin B (AmBisome®) had improved survival over those given either treatment alone, indicating a benefit to VesiVax® Af3/9 vaccination even in the case of infections that require follow-up antifungal treatment. These data demonstrate that prophylactic vaccination with VesiVax® Af3/9 is a promising method of protection against invasive pulmonary aspergillosis even as the changing face of the disease renders current therapies ineffective.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Slarve M, Holznecht N, Reza H, et al. Recombinant Aspergillus fumigatus antigens Asp f 3 and Asp f 9 in liposomal vaccine protect mice against invasive pulmonary aspergillosis. Vaccine. 2022. PMID: 35680499. doi:10.1016/j.vaccine.2022.05.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。